Novel rearrangements of an N-oxide degradate formed from oxidation of a morpholine acetal substance P antagonist

Journal of Pharmaceutical Sciences

Volumn 93, Issue 8, 2004, Pages 1957-1961

  Zhao, Zhongxi Zack ^a,b   Qin, Xue Zhi ^a   Wu, Allen ^a   Yuan, Yang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Metabasis Therapeutics Inc   (United States)

Author keywords

LC MS and MS MS; N oxide; Oxidation; Rearrangement; Substance P antagonist

Indexed keywords

5 [2 [1 (3,5 BISTRIFLUOROMETHYLPHENYL)ETHOXY] 3 (4 FLUOROPHENYL)MORPHOLIN 4 YLMETHYL] 3H [1,2,3] TRIAZOL 4 YLMETHYLDIMETHYLAMINE; MORPHOLINE ACETAL; MORPHOLINE DERIVATIVE; MW 591; OXIDE; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DEGRADATION; DRUG FORMULATION; DRUG POTENCY; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; STRUCTURE ANALYSIS; THERMAL ANALYSIS;

EID: 3843121106     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20115     Document Type: Article

References (12)

1. Hökfelt T, Pernow B, Wahren J. 2001. Substance P: A pioneer amongst neuropeptides. J Intern Med 247:27-40.
2. Seward EM, Swain CJ. 1999. Neurokinin receptor antagonists. Expert Opin Ther Pat 9:571.3.
3. Kramer MS, Cutler N, Feighner J, et al. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
4. Patel L, Lindley C. 2003. Aprepitant-A novel NK1-receptor antagonist. Expert Opin Pharmacother 4:2279-2296.
5. Harrison T, Owens AP, Willaims BJ, Swain CJ, Williams A, Carlson EJ, Rycroft W, Tattersall D, Cascieri MA, Chicchi GG, Sadowski S, Rupniak NM, Hargreaves RJ. 2001. Water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. J Med Chem 44:4296-4299.
6. Rupniak NMJ, Carlson EJ, Webb JK, et al. 2001. Comparison of the phenotype of NK1R -/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497-508.
7. Kamel A, Zandi K, Massefski W. 2003. Identification of the degradation product of ezlopitant, a non-peptidic substance P antagonist receptor, by hydrogen deuterium exchange, electrospray ionization tandem mass spectrometry (ESI/MS/MS) and nuclear magnetic resonance (NMR) spectroscopy. J Pharmaceut Biomed Anal 31:1211-1222.
8. Albini A. 1993. Synthetic utility of amine N-oxides. Synthesis 3:263-277.
9. Penkett CS, Simpson ID. 2001. Oxidative rearrangement of bicyclic 2-alkenyl aziridines. Tetrahedron Lett 42:3029-3032.
10. Qin XZ, Frech P. 2001. Liquid chromatography (LC/MS) identification of photooxidative degradates of crystalline and amorphous MK-912. J Pharmaceut Sci 90:833.
11. Grieco P, Clark JD, Jagoe CT. 1991. [1,3] Sigmatropic rearrangement of allyl vinyl ethers at ambient temperature in 3.0 M lithium perchlorate-diethyl ether. J Am Chem Soc 113:5488-5489.
12. Brands KMJ, Payack JF, Rosen JD, Nelson TD, Candelario A, Huffman MA, Zhao MM, Li J, Craig B, Song ZJ, Tschaen DM, Hansen K, Devine PN, Pye PJ, Rossen K, Dormer PG, Reamer RA, Welch CJ, Mathre DJ, Tsou NN, McNamara JM, Reider PJ. 2003. An efficient synthesis of NK1 receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. J Am Chem Soc 125:2129-2135.